Nai-Jung Chiang

Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy

Chen‐Han Chueh, Yi‐Wen Tsai, Zi-Rong Chen et al. · PharmacoEconomics · 2022 · 17 citations

Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

Nai-Jung Chiang, Kien Thiam Tan, Li‐Yuan Bai et al. · Clinical Cancer Research · 2022 · 15 citations · Full text

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

Zi-Rong Chen, Chen‐Han Chueh, Nai-Jung Chiang et al. · Cost Effectiveness and Resource Allocation · 2023 · 13 citations · Full text

Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy

Kuan-Chang Lai, Yen‐Hao Chen, Yi-Ping Hung et al. · Hepatology International · 2024 · 11 citations · Full text

DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer

Chi–Che Hsieh, Tingwei Li, Chun-Chun Li et al. · Oncogenesis · 2024 · 10 citations · Full text